Filter by Event: IDWeek 2024
In vitro Activity of Gepotidacin Tested Against Molecularly Characterized Escherichia coli Isolates Responsible for Urinary Tract Infections in the US (2019–2022)
In vitro Activity of Gepotidacin Tested Against Molecularly Characterized <i>Escherichia coli</i> Isolates Responsible for Urinary Tract Infections in the US (2019–2022). Lead author: Rodrigo E. Mendes, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1060
Activity of aztreonam-avibactam against Enterobacterales isolated from patients with intra-abdominal infection from United States medical centers (2019–2023)
Activity of aztreonam-avibactam against Enterobacterales isolated from patients with intra-abdominal infection from United States medical centers (2019–2023)Lead author: Helio S. Sader, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1081
In vitro Activity of Gepotidacin against Klebsiella pneumoniae, Including Molecularly Characterized ESBL and Carbapenemase Positive Subsets Causing Urinary Tract Infections in the United States (2019–2022)
<i>In vitro</i> Activity of Gepotidacin against <i>Klebsiella pneumoniae</i>, Including Molecularly Characterized ESBL and Carbapenemase Positive Subsets Causing Urinary Tract Infections in the United States (2019–2022). Lead author: Rodrigo E. Mendes, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1059
In vitro Activity of Gepotidacin against Klebsiella pneumoniae, Including Molecularly Characterized Fluoroquinolone Not Susceptible Subsets Causing Urinary Tract Infections in the United States (2019–2022)
<i>In vitro</i> Activity of Gepotidacin against <i>Klebsiella pneumoniae</i>, Including Molecularly Characterized Fluoroquinolone Not Susceptible Subsets Causing Urinary Tract Infections in the United States (2019–2022). Lead author: Rodrigo E. Mendes, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1061
In vitro Activity of Gepotidacin and Comparator Agents Against a Collection of Klebsiella pneumoniae Urine Isolates Collected from the United States during 2019–2022
<i>In vitro</i> Activity of Gepotidacin and Comparator Agents Against a Collection of <i>Klebsiella pneumoniae</i> Urine Isolates Collected from the United States during 2019–2022. Lead author: S. J. Ryan Arends, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #1062
Aztreonam-Avibactam Activity against Gram-negative Bacteria Isolated from Patients with Pneumonia from Europe, Asia, and Latin America (2021–2023)
Aztreonam-Avibactam Activity against Gram-negative Bacteria Isolated from Patients with Pneumonia from Europe, Asia, and Latin America (2021–2023). Lead author: Helio S. Sader, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1080
Antimicrobial Susceptibility of Enterobacterales Causing Infection in the Elderly: Focus on Aztreonam-Avibactam and Recently Approved β-Lactamase Inhibitor Combinations
Antimicrobial Susceptibility of Enterobacterales Causing Infection in the Elderly: Focus on Aztreonam-Avibactam and Recently Approved β-Lactamase Inhibitor
Combinations. Lead author: Helio S. Sader, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1082
Antimicrobial Activity of Aztreonam- Avibactam and Comparator Agents against a Large Collection of Stenotrophomonas maltophilia Isolates Collected in United States Medical Centers (2019–2023)
Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents against a Large Collection of <i>Stenotrophomonas maltophilia</i> Isolates Collected in United States Medical Centers (2019–2023). Lead author: Timothy B. Doyle, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1083
Antimicrobial Activity of Aztreonam- Avibactam and Other β-Lactamase Inhibitor Combinations Tested against Enterobacterales Isolates from Pediatric Patients from United States Medical Centers (2019–2023)
Antimicrobial Activity of Aztreonam-Avibactam and Other β-Lactamase Inhibitor Combinations Tested against Enterobacterales Isolates from Pediatric Patients from United States Medical Centers (2019–2023). Lead author: Helio S. Sader, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1084
Characterization of Enterobacter cloacae and Citrobacter freundii species complex isolates with decreased susceptibility to cephalosporins from United States hospitals and activity of aztreonam-avibactam and comparator agents (2019–2023)
Characterization of <i>Enterobacter cloacae</i> and <i>Citrobacter freundii</i> species complex isolates with decreased susceptibility to cephalosporins from United States hospitals and activity of aztreonam-avibactam and comparator agents (2019–2023). Lead author: Helio S. Sader, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1085
Activity of rezafungin against clinical isolates of uncommon species of Candida spp.
Activity of rezafungin against clinical isolates of uncommon species of <i>Candida</i> spp. Lead author: Marisa L. Winkler, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #1095
Activity of Ibrexafungerp and Comparator Antifungals Tested Against Candida and Aspergillus Isolates Collected from Invasive Infections in a Global Surveillance Program in 2023
Activity of Ibrexafungerp and Comparator Antifungals Tested Against <i>Candida</i> and <i>Aspergillus</i> Isolates Collected from Invasive Infections in a Global Surveillance Program in 2023. Lead author: Marisa L. Winkler, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1096
Activity of Isavuconazole and Comparator Agents against Pediatric Fungal Isolates Collected from 2017–2023 in a Global Surveillance Program
Activity of Isavuconazole and Comparator Agents against Pediatric Fungal Isolates Collected from 2017–2023 in a Global Surveillance Program. Lead author: Marisa L. Winkler, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1168
Occurrence of β-lactamases among Enterobacterales isolates from United States Hospitals in a 10-year period: Report from the International Network for Optimal Resistance Monitoring (INFORM) Program
Occurrence of β-lactamases among Enterobacterales isolates from United States Hospitals in a 10-year period: Report from the International Network for Optimal Resistance Monitoring (INFORM) Program. Lead author: Mariana Castanheira, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1351
Activity of Cefiderocol against Carbapenem Non-susceptible Enterobacterales, Including Molecularly Characterized Multidrug-Resistant Clinical Isolates, Causing Infections in United States Hospitals (2020–2023)
Activity of Cefiderocol against Carbapenem Non-susceptible Enterobacterales, Including Molecularly Characterized Multidrug-Resistant Clinical Isolates, Causing Infections in United States Hospitals (2020–2023). Lead author: Rodrigo E. Mendes, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1360
Cefiderocol Activity against Pseudomonas aeruginosa, Including Resistant Subsets and Isolates Carrying Carbapenemase β-lactamase Genes, from United States Hospitals (2020–2023)
Cefiderocol Activity against <i>Pseudomonas aeruginosa</i>, Including Resistant Subsets and Isolates Carrying Carbapenemase β-lactamase Genes, from United States Hospitals (2020–2023). Lead author: Rodrigo E. Mendes, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1361
Cefiderocol Activity against Carbapenem-Resistant Acinetobacter baumannii-calcoaceticus Complex, Including Molecularly Characterized Clinical Isolates, Causing Infections in United States Hospitals (2020–2023)
Cefiderocol Activity against Carbapenem-Resistant <i>Acinetobacter baumannii-calcoaceticus</i> Complex, Including Molecularly Characterized Clinical Isolates, Causing Infections in United States Hospitals (2020–2023). Lead author: Rodrigo E. Mendes, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1362
Cefiderocol Activity against Clinical Enterobacterales Isolates Carrying Metallo-β-Lactamase Genes in United States and European Hospitals (2020–2023)
Cefiderocol Activity against Clinical Enterobacterales Isolates Carrying Metallo-β-Lactamase Genes in United States and European Hospitals (2020–2023). Lead author: Rodrigo E. Mendes, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1363
Cefiderocol Activity against Pseudomonas aeruginosa Clinical Isolates Carrying Metallo-β-Lactamase Genes in United States and European Hospitals (2020–2023)
Cefiderocol Activity against <i>Pseudomonas aeruginosa</i> Clinical Isolates Carrying Metallo-β-Lactamase Genes in United States and European Hospitals (2020–2023). Lead author: Rodrigo E. Mendes, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #1364
In vitro Activity of Ceftobiprole Against Prominent Methicillin-resistant Staphylococcus aureus Clonal Groups Collected Through the SENTRY Antimicrobial Surveillance Program
<i>In vitro</i> Activity of Ceftobiprole Against Prominent Methicillin-resistant <i>Staphylococcus aureus</i> Clonal Groups Collected Through the SENTRY Antimicrobial Surveillance Program. Lead author: John H. Kimbrough, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1526
Update on the Activity of Ceftobiprole against Gram-positive Clinical Bacterial Isolates Causing Skin and Skin-structure Infections in the United States (2016–2020)
Update on the Activity of Ceftobiprole against Gram-positive Clinical Bacterial Isolates Causing Skin and Skin-structure Infections in the United States (2016–2020). Lead author: Joshua M. Maher, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P1527
In vitro activity of omadacycline and comparator agents against a collection of Neisseria gonorrhoeae urine isolates collected from the United States during 2018-2020
<i>In vitro</i> activity of omadacycline and comparator agents against a collection of <i>Neisseria gonorrhoeae</i> urine isolates collected from the United States during 2018-2020. Lead author: S.J. Ryan Arends, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #1528
Surveillance of omadacycline in vitro activity against 35,000 bacterial clinical isolates from the United States (2019–2023)
Surveillance of omadacycline in vitro activity against 35,000 bacterial clinical isolates from the United States (2019–2023). Lead author: Michael D. Huband, IDWeek 2024, October 16-19, Los Angeles, CA, USA
Poster #P411
